Ipilimumab/nivolumabImmune related myositis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1827卷 / 1期

关键词：

D O I：

10.1007/s40278-020-84940-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：185 / 185

相关论文

共 50 条

[31] Ipilimumab/nivolumabImmune-mediated hypophysitis: case report
Reactions Weekly, 2021, 1859 (1) : 199 - 199
[32] Ipilimumab/nivolumabImmune-mediated colitis: case report
Reactions Weekly, 2024, 2022 (1) : 155 - 155
[33] Ipilimumab/nivolumabImmune-mediated cholangitis : case report
Reactions Weekly, 2024, 2021 (1) : 269 - 269
[34] Ipilimumab/nivolumabImmune-mediated colitis: case report
Reactions Weekly, 2021, 1836 (1) : 436 - 436
[35] Ipilimumab/nivolumabImmune-mediated colitis: case report
Reactions Weekly, 2018, 1729 (1) : 151 - 151
[36] Ipilimumab/pembrolizumabInflammatory myositis: case report
Reactions Weekly, 2019, 1753 (1) : 205 - 205
[37] Ipilimumab/nivolumabImmune-related hepatitis: 2 case reports
Reactions Weekly, 2020, 1807 (1) : 104 - 104
[38] Ipilimumab/nivolumabImmune-mediated granulomatous pneumonitis: case report
Reactions Weekly, 2020, 1808 (1) : 158 - 158
[39] Ipilimumab/nivolumabImmune-related pneumonitis: 2 case reports
Reactions Weekly, 2020, 1813 (1) : 137 - 137
[40] Ipilimumab/nivolumabImmune mediated type I diabetes: case report
Reactions Weekly, 2018, 1728 (1) : 198 - 198

← 1 2 3 4 5 →